UK markets closed

iBio, Inc. (0JV0.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
3.51450.0000 (0.00%)
At close: 08:14AM CET
Full screen
Previous close3.5145
Open3.5145
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range3.5145 - 3.5145
52-week range3.5145 - 46.7600
VolumeN/A
Avg. volume0
Market cap12.245M
Beta (5Y monthly)-3.84
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date13 May 2024 - 17 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

    – Deal includes $1 million upfront and potential future milestone payments – – iBio’s proprietary therapeutic pipeline will now be comprised entirely of promising immuno-oncology candidates – BRYAN, Texas and SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announces today that it has entered into an asset purchase agreement (“Agreement”) with Otsuka Pharmaceutical Co., Ltd. (“Otsuka”), p

  • GlobeNewswire

    iBio Announces Participation in 23rd Annual PepTalk Conference

    - VP of Platform Technologies, Matt Greving, to give podium presentation on enhancing bispecific T-cell engager discovery and development with machine learning -BRYAN, Texas and SAN DIEGO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that Matthew P. Greving Ph.D., its Vice President and Head of Platform Technologies and Machine Learning, will give a podium presentation titled "En

  • GlobeNewswire

    iBio Amends and Extends Maturity of Credit Agreement

    – Extends maturity date to March 29, 2024 – – Allows for more time to complete planned divestiture of legacy CDMO business - BRYAN, Texas and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced its wholly owned subsidiary, iBio CDMO LLC, and its lender, Woodforest National Bank (“Woodforest”), have entered into an amendment (the “Amendment”) to the Credit Agreement dated Nove